The Q2 beat is entirely driven by a one-time upfront payment from the NIT license, masking a decline in direct Endari sales. Traders should monitor the 10-Q for details on the sustainability of the NIT royalty stream and any update on the going-concern risk, as the underlying business fundamentals remain weak.
Price Chart
Executive Summary
Emmaus Life Sciences reported Q2 2026 net revenues of $6.3M, a 124% increase YoY, driven by recognizing upfront revenue from the NIT license agreement. The company swung to a net income of $1.3M ($0.02 EPS) from a net loss of $1.1M (-$0.02 EPS) in Q2 2025, while also reducing operating expenses. However, the revenue boost is non-recurring/licensing-based, and the company still carries a significant stockholders' deficit of -$66.2M with a going-concern risk flagged in forward-looking statements, making the underlying business trends unclear.
Key Financial Metrics
Key Facts
- Net revenues for Q2 2026 were $6.3M, up 124% from $2.8M in Q2 2025, primarily due to the NIT license arrangement.
- Net income was $1.3M ($0.02 basic EPS) vs. a net loss of $1.1M (-$0.02 basic EPS) in Q2 2025.
- Operating expenses decreased to $2.1M from $3.0M, partly due to the transfer of the sales force to NIT.
- Cash and cash equivalents were $2.8M at June 30, 2026, up from $2.1M at December 31, 2025.
- The company has a significant stockholders' deficit of $66.2M and total current liabilities of $66.1M, with a going-concern risk noted in forward-looking statements.
- Direct Endari sales decreased, partially offsetting the NIT license revenue.
Financial Impact
Q2 2026 net revenues of $6.3M (up 124% YoY) and net income of $1.3M, compared to a net loss of $1.1M in Q2 2025. The revenue increase is largely from a non-recurring licensing deal.
Risk Factors
- Going-concern risk noted in forward-looking statements.
- Revenue boost is non-recurring; direct Endari sales declined.
- Significant stockholders' deficit of $66.2M and high current liabilities of $66.1M.
- Dependence on NIT for future sales and distribution of Endari in the U.S. and Canada.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-089912 |
| Document: ea0302099-8k_emmaus.htm | 0001213900-26-089912 |
| Document: 0001213900-26-089912-index-headers.html | 0001213900-26-089912 |
| Document: 0001213900-26-089912-index.html | 0001213900-26-089912 |
| Document: 0001213900-26-089912.txt | 0001213900-26-089912 |
| 8-K Data (Synthetic) | 0001213900-26-089912 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 14, 2026 10w ago | 8-K | $0.0115 | awaiting T+60 | — | $0.0576 (+400.61%) |
Apr 17, 2026 27w ago | 8-K | $0.009100 $0.0115 | ▲ +25.93% | ▲ +19.16% | $0.0576 (+532.64%) |
Mar 31, 2026 29w ago | 8-K | $0.0150 $0.0100 | ▲ +33.33% | ▲ +45.72% | $0.0576 (−283.80%) |
Mar 4, 2026 33w ago | 8-K | $0.0145 $0.009600 | ▼ −33.79% | ▼ −45.09% | $0.0576 (+297.03%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers